Endobronchial Ultrasound Biopsy Market Size, Share, Growth, and Industry Analysis, By Type (EBUS-TBNA,Bronchoscopes and probes,Biopsy forceps and needles,Ultrasound processor and needles,Cytology brushes and spray catheter,Others), By Application (Hospitals,Specialty Centers,Diagnostic Centers,Ambulatory Surgical Centers), Regional Insights and Forecast to 2035

Endobronchial Ultrasound Biopsy Market Overview

The global Endobronchial Ultrasound Biopsy Market size is projected to grow from USD 726.2 million in 2026 to USD 783.72 million in 2027, reaching USD 1442.03 million by 2035, expanding at a CAGR of 7.92% during the forecast period.

The Endobronchial Ultrasound Biopsy Market has gained global recognition as 68% of lung cancer diagnostics now integrate EBUS techniques, compared to only 42% a decade earlier. With lung cancer accounting for 11.4% of global cancer cases, adoption of endobronchial ultrasound biopsy devices has expanded to cover 71% of tertiary hospitals worldwide. Clinical trials across 34 countries demonstrated that EBUS biopsy provides 87% accuracy in mediastinal staging, outperforming traditional bronchoscopy by 28%.

The USA represents nearly 31% of the global Endobronchial Ultrasound Biopsy Market, with over 5,200 hospitals offering EBUS-guided biopsy services. Approximately 64% of lung cancer patients in the USA undergo EBUS-TBNA for mediastinal staging, reflecting its clinical superiority. The American Cancer Society reported that 13% of all cancers diagnosed in the country are lung cancers, making EBUS biopsy a crucial diagnostic tool. Around 72% of U.S. specialty centers have adopted hybrid bronchoscopy systems with ultrasound capabilities, compared to only 41% five years ago.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 71% growth in demand for minimally invasive diagnostic solutions drives adoption of EBUS biopsy devices across hospitals and specialty centers.
• Major Market Restraint: 46% of diagnostic facilities in developing nations report limited access to high-cost EBUS systems, restricting wider adoption.
• Emerging Trends: 63% rise in AI-enabled imaging software integration enhances precision of EBUS biopsy across global diagnostic facilities.
• Regional Leadership: North America holds 37% share, Europe 28%, and Asia-Pacific 26%, with the Middle East & Africa covering 9%.
• Competitive Landscape: Olympus Corporation leads with 24% market share, followed by Medtronic with 22% and Boston Scientific at 18%.
• Market Segmentation: Hospitals account for 54% share, specialty centers 21%, diagnostic centers 17%, and ambulatory surgical centers 8%.
• Recent Development: 59% of manufacturers launched upgraded biopsy needles between 2023–2025, improving diagnostic yield and patient outcomes.

Endobronchial Ultrasound Biopsy Market Latest Trends

The Endobronchial Ultrasound Biopsy Market is witnessing a surge in demand for disposable biopsy tools, with 62% of hospitals now preferring single-use needles and forceps to reduce infection risks. Integration of AI-enabled imaging has increased by 47% since 2022, significantly improving diagnostic accuracy in identifying lymph node metastasis. Robotic bronchoscopy systems, integrated with ultrasound biopsy, have been adopted by 34% of top-tier hospitals worldwide, showing a 29% increase in adoption over two years.

Hybrid diagnostic solutions combining EBUS with PET-CT scans now represent 41% of procedures in specialized oncology centers, compared to 27% previously. Additionally, 69% of cytology laboratories report higher sample adequacy using spray catheters during EBUS-guided biopsies, improving patient outcomes. More than 55% of Asia-Pacific hospitals invested in EBUS biopsy infrastructure during 2024–2025, driven by rising lung cancer incidence, which represents 14% of overall cancer cases in the region.

Endobronchial Ultrasound Biopsy Market Dynamics

DRIVER

"Rising adoption of minimally invasive diagnostics"

Globally, 74% of tertiary hospitals now prefer EBUS biopsy procedures over mediastinoscopy due to reduced complication rates and 32% higher diagnostic accuracy. Patient preference for minimally invasive methods has surged by 61% within the last five years, while oncology centers reported 47% faster recovery times in EBUS cases. Adoption of EBUS in specialty centers has increased from 46% to 68% between 2020 and 2024, clearly positioning minimally invasive diagnostics as the strongest driver for this market’s growth.

RESTRAINT

"High cost of advanced EBUS systems"

Around 42% of diagnostic centers in developing economies face affordability issues with advanced EBUS biopsy systems, limiting wider adoption. High procurement and maintenance costs contribute to nearly 28% of their annual operating expenses. Single-use accessories, adopted by 62% of hospitals, further increase expenditure compared to reusable devices. Budget constraints mean that 49% of smaller healthcare facilities rely on traditional biopsy tools, slowing advanced technology penetration.

OPPORTUNITY

"Expansion in personalized medicine diagnostics"

Over 66% of oncology facilities worldwide now integrate biomarker testing with EBUS biopsy samples, enabling highly targeted treatment pathways. Precision oncology adoption has risen by 54% globally, pushing demand for accurate tissue sampling. Nearly 58% of pharmaceutical research trials now include EBUS-derived biopsy samples for drug development validation. Hospitals investing in personalized diagnostic infrastructure grew from 39% to 63% between 2019 and 2024.

CHALLENGE

"Shortage of trained pulmonologists"

Globally, only 58% of pulmonologists are fully trained in performing EBUS biopsy procedures, creating significant capacity gaps. In developing regions, this percentage drops to 41%, while training coverage in North America is 74% and Europe 65%. Approximately 29% of hospitals report delayed procedure schedules due to specialist shortages. The lack of skilled professionals results in 21% lower utilization rates of installed EBUS equipment in emerging markets.

Endobronchial Ultrasound Biopsy Market Segmentation

The Endobronchial Ultrasound Biopsy Market segmentation shows hospitals holding 54% share, specialty centers 21%, diagnostic centers 17%, and ambulatory surgical centers 8%, while EBUS-TBNA dominates type-based adoption with 39%, followed by bronchoscopes, biopsy forceps, processors, cytology brushes, and other accessories.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

EBUS-TBNA: EBUS-TBNA accounts for 39% of global procedures and is considered the most reliable method for mediastinal staging. Around 71% of oncology centers utilize it for lymph node biopsies, achieving 87% accuracy compared to 59% with traditional bronchoscopy. Adoption increased from 52% in 2019 to 68% in 2024, largely driven by its minimally invasive nature.

The EBUS-TBNA segment is projected at USD 262.4 million in 2025, holding a 39% share, expected to reach USD 538.6 million by 2034 at a CAGR of 8.05%.

Top 5 Major Dominant Countries in the EBUS-TBNA Segment

• United States: At USD 91.4 million in 2025, holding 34.8% share, projected to reach USD 188.5 million by 2034 with a strong CAGR of 8.14%.
• Germany: Estimated at USD 26.2 million in 2025 with 10% share, forecast to rise to USD 55.6 million by 2034, achieving CAGR growth of 8.67%.
• China: Valued at USD 31.4 million in 2025 with 12% share, set to increase to USD 64.7 million by 2034, expanding steadily at 8.39% CAGR.
• Japan: Market size USD 18.3 million in 2025 with 7% share, anticipated to grow to USD 38.9 million by 2034 with CAGR reaching 8.72%.
• United Kingdom: At USD 13.1 million in 2025, covering 5% share, projected to reach USD 27.8 million by 2034, recording CAGR expansion of 8.46%.

Bronchoscopes and Probes: Bronchoscopes and probes represent 21% market share, with 48% of hospitals using advanced models for guided navigation. Approximately 57% of pulmonologists reported improved visualization during biopsy procedures with upgraded probes compared to older devices. Flexible bronchoscopes now dominate 62% of usage due to their ability to reach distal airways. Regional data indicates North America accounts for 38% of bronchoscopic usage, while Asia-Pacific holds 29%.

Bronchoscopes and probes are valued at USD 141.3 million in 2025, accounting for a 21% share, projected to reach USD 275.5 million by 2034 with a CAGR of 7.68%.

Top 5 Major Dominant Countries in the Bronchoscopes and Probes Segment

• United States: Valued at USD 46.6 million in 2025 with 33% share, forecasted to hit USD 91.7 million by 2034, growing steadily at CAGR 7.91%.
• Germany: At USD 14.1 million in 2025 with 10% share, projected to expand to USD 29.3 million by 2034, maintaining CAGR progress of 8.05%.
• China: Estimated at USD 15.5 million in 2025 with 11% share, forecast to achieve USD 31.6 million by 2034, rising at CAGR 8.12% consistently.
• Japan: Valued at USD 9.8 million in 2025 with 7% share, expected to reach USD 20.1 million by 2034, posting CAGR acceleration of 8.19%.
• France: Market size USD 8.4 million in 2025 with 6% share, forecast to grow to USD 17.2 million by 2034, achieving CAGR of 8.10%.

Biopsy Forceps and Needles: Biopsy forceps and needles hold a 16% share in the Endobronchial Ultrasound Biopsy Market, with 63% of diagnostic centers preferring disposable tools to limit infection risk. Advances in design increased sample adequacy rates by 31% compared to previous generations. Hospitals in Europe account for 34% of the global demand for precision biopsy needles, while Asia-Pacific represents 28%.

Biopsy forceps and needles are forecasted at USD 107.7 million in 2025, capturing a 16% share, likely to reach USD 216.1 million by 2034 with a CAGR of 8.10%.

Top 5 Major Dominant Countries in the Biopsy Forceps and Needles Segment

• United States: Valued at USD 36.6 million in 2025 with 34% share, forecast to reach USD 75.3 million by 2034, advancing at CAGR of 8.25%.
• Germany: At USD 10.7 million in 2025 holding 10% share, projected to expand to USD 21.6 million by 2034, marking CAGR performance of 8.14%.
• China: Estimated at USD 12.2 million in 2025 with 11% share, set to rise to USD 24.8 million by 2034, maintaining CAGR of 8.20%.
• Japan: Valued at USD 7.5 million in 2025 with 7% share, anticipated to grow to USD 15.4 million by 2034 with CAGR reaching 8.32%.
• United Kingdom: At USD 5.9 million in 2025 with 5.5% share, forecast to hit USD 11.9 million by 2034, holding CAGR growth at 8.10%.

Ultrasound Processor and Needles: Ultrasound processors and needles contribute 12% of market demand, with 71% of advanced hospitals adopting processors equipped with digital imaging storage. Recent developments improved image clarity by 29%, enhancing diagnostic reliability. Adoption rates rose from 44% in 2020 to 61% in 2024. More than 53% of specialty centers now use dual-function processors that integrate real-time navigation with biopsy guidance.

The ultrasound processor and needles segment is valued at USD 80.7 million in 2025, representing a 12% share, projected to reach USD 159.1 million by 2034 at a CAGR of 7.96%.

Top 5 Major Dominant Countries in the Ultrasound Processor and Needles Segment

• United States: Market size USD 27.4 million in 2025 with 34% share, forecast to reach USD 55.5 million by 2034, achieving CAGR growth of 8.05%.
• Germany: Valued at USD 8.0 million in 2025 with 10% share, projected to rise to USD 15.9 million by 2034, progressing at CAGR of 7.94%.
• China: Estimated at USD 8.8 million in 2025 with 11% share, forecast to hit USD 17.6 million by 2034, expanding steadily at CAGR 8.01%.
• Japan: At USD 5.6 million in 2025 with 7% share, expected to reach USD 11.4 million by 2034, posting CAGR expansion of 8.23%.
• France: Market size USD 4.8 million in 2025 with 6% share, projected to grow to USD 9.7 million by 2034, maintaining CAGR of 8.15%.

Cytology Brushes and Spray Catheter: Cytology brushes and spray catheters hold a 7% share in the global market. Adoption has grown by 41% over the last five years due to higher diagnostic accuracy in cytology labs. Hospitals using spray catheters report 28% improvement in sample adequacy. North America accounts for 33% of the usage, while Asia-Pacific follows closely at 29%.

Cytology brushes and spray catheters are estimated at USD 47.1 million in 2025, covering a 7% share, expected to reach USD 94.5 million by 2034 at a CAGR of 8.16%.

Top 5 Major Dominant Countries in the Cytology Brushes and Spray Catheter Segment

• United States: Valued at USD 16.0 million in 2025 with 34% share, forecast to reach USD 32.3 million by 2034, advancing at CAGR of 8.23%.
• Germany: Market size USD 4.7 million in 2025 with 10% share, expected to grow to USD 9.5 million by 2034, recording CAGR at 8.11%.
• China: At USD 5.2 million in 2025 with 11% share, forecast to reach USD 10.5 million by 2034, showing CAGR development of 8.13%.
• Japan: Estimated at USD 3.3 million in 2025 with 7% share, projected to hit USD 6.8 million by 2034, maintaining CAGR of 8.28%.
• France: Valued at USD 2.8 million in 2025 with 6% share, forecasted to rise to USD 5.7 million by 2034, posting CAGR of 8.22%.

Others: Other devices, including navigation systems and supporting biopsy accessories, account for 5% of the market. Usage grew by 18% between 2020 and 2024, driven by demand for digital navigation platforms. Approximately 47% of hospitals with advanced oncology units reported installing supporting systems to improve diagnostic yield. North America contributes 38% to this category, while Europe holds 27%.

The “Others” category is forecast at USD 33.7 million in 2025, representing a 5% share, projected to reach USD 66.4 million by 2034 at a CAGR of 7.90%.

Top 5 Major Dominant Countries in the Others Segment

• United States: Estimated at USD 11.5 million in 2025 with 34% share, forecast to reach USD 22.8 million by 2034, advancing at CAGR growth of 7.98%.
• Germany: Valued at USD 3.4 million in 2025 with 10% share, projected to rise to USD 6.7 million by 2034, holding CAGR at 7.87%.
• China: At USD 3.7 million in 2025 with 11% share, expected to hit USD 7.4 million by 2034, expanding at CAGR of 7.95%.
• Japan: Market size USD 2.3 million in 2025 with 7% share, projected to reach USD 4.7 million by 2034, marking CAGR expansion of 8.05%.
• France: Estimated at USD 2.0 million in 2025 with 6% share, forecasted to grow to USD 4.0 million by 2034, maintaining CAGR at 8.02%.

BY APPLICATION

Hospitals: Hospitals dominate the Endobronchial Ultrasound Biopsy Market with a 54% share, reflecting their role as primary healthcare providers for cancer diagnostics. Nearly 78% of tertiary hospitals have incorporated EBUS biopsy into their oncology units. North America represents 37% of hospital-based EBUS adoption, followed by Europe at 28%. In developing countries, hospital adoption increased from 41% in 2020 to 59% in 2024.

Hospitals dominate the market with USD 363.3 million in 2025, capturing a 54% share, expected to reach USD 738.5 million by 2034 at a CAGR of 8.01%.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: Estimated at USD 123.5 million in 2025 with 34% share, projected to hit USD 251.5 million by 2034, advancing at CAGR of 8.14%.
• Germany: Valued at USD 36.3 million in 2025 with 10% share, forecast to rise to USD 73.8 million by 2034, achieving CAGR of 8.12%.
• China: At USD 40.0 million in 2025 with 11% share, anticipated to reach USD 81.3 million by 2034, recording CAGR progression of 8.16%.
• Japan: Market size USD 24.6 million in 2025 with 7% share, expected to grow to USD 49.9 million by 2034 at CAGR of 8.25%.
• United Kingdom: Estimated at USD 18.1 million in 2025 with 5% share, forecast to hit USD 36.9 million by 2034 with CAGR of 8.19%.

Specialty Centers: Specialty centers account for 21% of market share, focusing primarily on oncology and pulmonology. Approximately 67% of these centers integrate EBUS biopsy with molecular diagnostic platforms for biomarker detection. North America leads with 34% of specialty center usage, while Asia-Pacific follows at 26%. Between 2020 and 2024, the number of specialty centers offering EBUS biopsy services increased by 42%.

Specialty centers are valued at USD 141.3 million in 2025, covering a 21% share, forecasted to rise to USD 281.0 million by 2034, growing at CAGR 7.95%.

Top 5 Major Dominant Countries in the Specialty Centers Application

• United States: At USD 48.0 million in 2025 with 34% share, forecast to hit USD 95.6 million by 2034, advancing at CAGR of 8.06%.
• Germany: Market size USD 14.1 million in 2025 with 10% share, projected to reach USD 28.1 million by 2034, maintaining CAGR 7.92%.
• China: Valued at USD 15.6 million in 2025 with 11% share, expected to achieve USD 31.1 million by 2034, showing CAGR expansion of 7.99%.
• Japan: Estimated at USD 9.8 million in 2025 with 7% share, forecasted to reach USD 19.6 million by 2034, delivering CAGR of 8.00%.
• France: At USD 8.4 million in 2025 with 6% share, projected to grow to USD 16.8 million by 2034, progressing at CAGR of 7.98%.

Diagnostic Centers: Diagnostic centers hold 17% share in the Endobronchial Ultrasound Biopsy Market, serving as cost-effective options for early-stage cancer evaluation. Approximately 49% of urban diagnostic centers have installed EBUS systems, compared to 21% in rural regions. Asia-Pacific accounts for 31% of diagnostic center demand, while Europe contributes 27%. Around 57% of diagnostic centers adopt cytology brushes for routine testing, while 43% integrate advanced spray catheters for complex sampling.

Diagnostic centers stand at USD 114.4 million in 2025, covering a 17% share, expected to reach USD 225.1 million by 2034 with a CAGR of 7.83%.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: Valued at USD 38.9 million in 2025 with 34% share, forecast to hit USD 76.5 million by 2034, advancing at CAGR of 7.89%.
• Germany: Estimated at USD 11.4 million in 2025 with 10% share, set to grow to USD 22.5 million by 2034, with CAGR at 7.85%.
• China: At USD 12.6 million in 2025 with 11% share, forecast to rise to USD 24.9 million by 2034, expanding steadily at CAGR 7.90%.
• Japan: Valued at USD 7.9 million in 2025 with 7% share, projected to reach USD 15.6 million by 2034, marking CAGR growth at 7.92%.
• France: Market size USD 6.8 million in 2025 with 6% share, forecast to reach USD 13.6 million by 2034, showing CAGR at 7.87%.

Ambulatory Surgical Centers: Ambulatory surgical centers represent 8% of the market, with rapid expansion in regions emphasizing outpatient care. Adoption of EBUS biopsy in these facilities grew by 36% between 2020 and 2024. North America dominates with 44% of ASC-based usage, while Europe holds 25%. Approximately 53% of ASCs prefer compact, portable ultrasound processors due to limited space availability.

Ambulatory surgical centers are projected at USD 53.8 million in 2025, representing 8% share, likely to reach USD 107.0 million by 2034, at a CAGR of 7.94%.

Top 5 Major Dominant Countries in the Ambulatory Surgical Centers Application

• United States: Market size USD 18.3 million in 2025 with 34% share, expected to reach USD 36.4 million by 2034, advancing at CAGR of 8.00%.
• Germany: Estimated at USD 5.3 million in 2025 with 10% share, projected to grow to USD 10.6 million by 2034, progressing at CAGR of 7.94%.
• China: Valued at USD 5.9 million in 2025 with 11% share, forecast to hit USD 11.8 million by 2034, holding CAGR growth of 7.96%.
• Japan: At USD 3.7 million in 2025 with 7% share, projected to reach USD 7.4 million by 2034, maintaining CAGR expansion of 7.97%.
• France: Market size USD 3.2 million in 2025 with 6% share, forecasted to grow to USD 6.3 million by 2034, achieving CAGR of 7.95%.

Endobronchial Ultrasound Biopsy Market Regional Outlook

North America leads with 37% share, followed by Europe at 28% and Asia-Pacific at 26%. The Middle East & Africa account for 9%, reflecting rising adoption, regional investments, and increased EBUS biopsy procedures across oncology and diagnostic facilities.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds 37% of the Endobronchial Ultrasound Biopsy Market, with the United States alone representing 31% share. Approximately 64% of lung cancer patients undergo EBUS biopsy across hospitals, while 72% of specialty centers integrate robotic bronchoscopy with ultrasound. Canada accounts for 5% regional share, driven by cancer screening programs.

The North America Endobronchial Ultrasound Biopsy Market is valued at USD 249.9 million in 2025, capturing a 37.1% share, projected to reach USD 504.7 million by 2034 at a CAGR of 8.02%.

North America – Major Dominant Countries

• United States: Valued at USD 208.0 million in 2025 with 83% regional share, expected to reach USD 420.3 million by 2034, advancing steadily at CAGR of 8.10%.
• Canada: Estimated at USD 21.2 million in 2025 holding 8.5% share, forecast to reach USD 42.8 million by 2034, achieving regional CAGR growth rate of 8.03%.
• Mexico: Market size USD 12.5 million in 2025 covering 5% share, projected to hit USD 25.6 million by 2034, growing consistently at CAGR of 8.06%.
• Cuba: Valued at USD 4.4 million in 2025 with 1.8% share, forecast to expand to USD 9.1 million by 2034, maintaining CAGR of 8.07%.
• Dominican Republic: Estimated at USD 3.8 million in 2025 with 1.5% share, expected to reach USD 7.8 million by 2034, recording CAGR performance of 8.00%.

EUROPE

Europe captures 28% share, led by Germany at 11% and the United Kingdom at 9%. Approximately 61% of European hospitals utilize EBUS-TBNA for mediastinal staging, while 58% of specialty centers integrate molecular testing with biopsy samples. France contributes 6% share with rapid adoption of disposable biopsy forceps. More than 65% of pulmonologists in Europe are trained in EBUS techniques.

The Europe Endobronchial Ultrasound Biopsy Market is forecasted at USD 188.4 million in 2025, accounting for a 28% share, anticipated to rise to USD 379.6 million by 2034 with a CAGR of 7.97%.

Europe – Major Dominant Countries

• Germany: Market size USD 65.9 million in 2025 with 35% regional share, projected to reach USD 134.2 million by 2034, expanding strongly with CAGR of 8.12%.
• United Kingdom: Valued at USD 45.2 million in 2025 covering 24% share, expected to hit USD 92.5 million by 2034, maintaining consistent CAGR growth at 8.03%.
• France: Estimated at USD 28.3 million in 2025 holding 15% share, forecast to reach USD 57.8 million by 2034, progressing at CAGR of 7.96%.
• Italy: Valued at USD 24.5 million in 2025 with 13% share, projected to grow to USD 50.1 million by 2034, delivering CAGR expansion of 8.00%.
• Spain: Market size USD 18.7 million in 2025 with 10% share, anticipated to rise to USD 38.0 million by 2034, advancing at CAGR of 8.04%.

ASIA-PACIFIC

Asia-Pacific holds 26% share, with China leading at 13% and Japan at 7%. Around 56% of hospitals in the region adopted EBUS biopsy devices in 2024–2025, compared to 41% five years ago. India accounts for 4% share, with rapid diagnostic center adoption increasing 29% since 2021. Nearly 62% of pulmonologists are trained in EBUS techniques across Asia-Pacific.

The Asia-Pacific Endobronchial Ultrasound Biopsy Market is projected at USD 175.0 million in 2025, representing a 26% share, forecast to increase to USD 351.7 million by 2034, registering a CAGR of 7.95%.

Asia-Pacific – Major Dominant Countries

• China: Valued at USD 87.5 million in 2025 with 50% regional share, forecast to reach USD 176.2 million by 2034, advancing steadily at CAGR of 7.98%.
• Japan: Market size USD 49.0 million in 2025 covering 28% share, projected to hit USD 98.6 million by 2034, recording CAGR growth of 8.01%.
• India: Estimated at USD 21.0 million in 2025 with 12% share, forecast to expand to USD 42.3 million by 2034, showing CAGR progression of 7.92%.
• South Korea: Valued at USD 10.5 million in 2025 with 6% share, expected to reach USD 21.1 million by 2034, achieving CAGR of 7.95%.
• Australia: Market size USD 7.0 million in 2025 with 4% share, projected to reach USD 13.5 million by 2034, maintaining CAGR growth at 7.90%.

MIDDLE EAST & AFRICA

The Middle East & Africa hold 9% share of the Endobronchial Ultrasound Biopsy Market. Saudi Arabia accounts for 3% and South Africa 2%, reflecting growing healthcare investments. Around 49% of tertiary hospitals in the region have installed EBUS biopsy systems, compared to 28% in 2020. Training adoption among pulmonologists remains lower at 44%, limiting utilization.

The Middle East & Africa Endobronchial Ultrasound Biopsy Market is valued at USD 60.7 million in 2025, holding a 9% share, projected to reach USD 122.2 million by 2034 with a CAGR of 7.90%.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: Valued at USD 18.2 million in 2025 with 30% share, forecast to hit USD 36.8 million by 2034, maintaining CAGR development of 7.95%.
• South Africa: Market size USD 12.1 million in 2025 with 20% share, projected to reach USD 24.3 million by 2034, progressing steadily with CAGR of 7.93%.
• United Arab Emirates: Estimated at USD 9.1 million in 2025 with 15% share, expected to grow to USD 18.5 million by 2034, marking CAGR 7.91%.
• Egypt: Valued at USD 7.3 million in 2025 with 12% share, forecast to reach USD 14.8 million by 2034, recording CAGR growth at 7.89%.
• Nigeria: Market size USD 6.0 million in 2025 with 10% share, projected to achieve USD 12.0 million by 2034, holding CAGR expansion of 7.92%.

List of Top Endobronchial Ultrasound Biopsy Companies

• Conmed Corporation
• Medtronic plc
• Olympus Corporation
• Fujifilm Corporation
• Boston Scientific Corporation
• Pentax Medical
• Cook Medical
• Veran Medical Technologies
• Medi-Globe GmbH
• Clinodevice

Top Companies:

• Olympus Corporation holds 24% global market share with extensive EBUS device portfolios.
• Medtronic follows with 22% share, driven by strong adoption of biopsy forceps and ultrasound processors across North America and Europe.

Investment Analysis and Opportunities

Investments in the Endobronchial Ultrasound Biopsy Market are increasing, with 62% of manufacturers prioritizing funding for disposable biopsy devices and 57% focusing on AI-enabled ultrasound imaging. Asia-Pacific attracted 34% of new EBUS biopsy equipment investments in 2024–2025, compared to 28% in North America and 23% in Europe.

Nearly 48% of recent investments target hybrid systems combining robotic bronchoscopy with EBUS biopsy. More than 41% of global clinical research funding is directed toward enhancing diagnostic yield from lymph node biopsies using EBUS-TBNA. With 69% of investors prioritizing early-stage cancer detection, the sector shows strong alignment with public health initiatives.

New Product Development

Between 2023–2025, 59% of manufacturers launched updated biopsy needles with improved flexibility, while 48% introduced processors with enhanced digital storage capabilities. Olympus introduced ultrathin bronchoscopes with 29% greater navigation capacity in 2024. Medtronic developed forceps with 33% higher sample yield compared to previous models.

Fujifilm integrated AI-assisted software into EBUS systems, raising diagnostic precision by 31%. More than 62% of manufacturers now prioritize single-use biopsy tools to prevent cross-contamination. Hybrid diagnostic devices integrating PET-CT scans with EBUS biopsy were launched by 41% of companies.

Five Recent Developments

• Olympus launched AI-assisted biopsy guidance in 2024, improving sample adequacy by 32%.
• Medtronic introduced advanced forceps in 2023, increasing diagnostic precision by 29%.
• Boston Scientific developed disposable catheters in 2024, raising cytology adequacy by 27%.
• Fujifilm launched integrated robotic bronchoscopy-EBUS systems in 2025, adopted by 18% of Tier-1 hospitals.
• Pentax Medical unveiled flexible bronchoscopes in 2025, improving navigation efficiency by 24%.

Report Coverage of Endobronchial Ultrasound Biopsy Market

This Endobronchial Ultrasound Biopsy Market Report covers type-based segmentation including EBUS-TBNA, bronchoscopes, biopsy forceps, ultrasound processors, cytology brushes, and related accessories. Application segments include hospitals, specialty centers, diagnostic centers, and ambulatory surgical centers.

The report provides a detailed regional outlook, highlighting North America at 37%, Europe at 28%, Asia-Pacific at 26%, and the Middle East & Africa at 9%. Competitive profiling includes Olympus, Medtronic, Boston Scientific, Fujifilm, and other global players. Investment trends show 62% focus on disposable biopsy devices and 57% on AI-driven ultrasound systems. New product developments highlight ultrathin probes, advanced forceps, and AI-enabled processors.

Endobronchial Ultrasound Biopsy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 726.2 Million in 2026
Market Size Value By	USD 1442.03 Million by 2035
Growth Rate	CAGR of 7.92% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : EBUS-TBNA Bronchoscopes and probes Biopsy forceps and needles Ultrasound processor and needles Cytology brushes and spray catheter Others By Application : Hospitals Specialty Centers Diagnostic Centers Ambulatory Surgical Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample